title: Expression of PLK1 and survivin in non-Hodgkin's lymphoma treated with CHOP.
abstract: OBJECTIVE
  The present study was designed to investigate the expression of Polo-like kinase 1 (PLK1) and survivin in non-Hodgkinos lymphoma (NHL).
  
  
  METHODS
  The expression of PLK1 and survivin were detected with immunohistochemical techniques.
  
  
  RESULTS
  The expression rate of PLK1 and survivin were 63.6% (56/88) and 79.5% (70/88) in NHL, respectively. PLK1 expression correlated with systemic symptoms, lactate dehydrogenase levels, and international prognostic index scores in B-NHL and T-NHL, while survivin did not.
  
  
  CONCLUSIONS
  PLK1 and survivin are both overexpressed in NHL. There is a significant relationship between the overexpression of PLK1 and clinical features.
authors.affiliation: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Liu
authors.forename: Min
authors.initials: M
authors.lastname: Zhang
authors.forename: Ping
authors.initials: P
authors.lastname: Zou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D000077022:Survivin; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult; D000097869:Polo-Like Kinase 1
chemical_list: D018797:Cell Cycle Proteins; D003520:Cyclophosphamide; D004317:Doxorubicin; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D011241:Prednisone; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000077022:Survivin; D014750:Vincristine; D000097869:Polo-Like Kinase 1; C107489:BIRC5 protein, human